The global dyspnea treatment market, valued at USD 5.90 billion in 2022, is expected to experience robust growth, projected to reach approximately USD 12.3 billion by 2033 with a CAGR of 6.9% from 2023 to 2033. This expansion is driven by the increasing availability of innovative drug delivery systems, such as inhalers and nebulizers, which …